To determine whether the engineered EVs induce lysosomal degradation of CD19 in B‐ALL target cells, as it did in 293‐CD19‐GFP cells, we treated SEM cells with CQ. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.